Viewpoint: A holistic view of innovation incentives and pharmaceutical policy reform

A full understanding of the IRA's impact on innovation requires considering not merely the number of new drugs that might come to market after the law's passage but the clinical value those new drugs deliver to patients.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...